Use in Pregnancy: The safety of desvenlafaxine in human pregnancy has not been established. Desvenlafaxine must only be administered to pregnant women if the expected benefits outweigh the possible risks. If desvenlafaxine is used until, or shortly before birth, discontinuation effects in the newborn should be considered.
Complications, including the need for respiratory support, tube feeding or prolonged hospitalization, have been reported in neonates exposed to SNRIs or SSRIs, late in the 3rd trimester. Such complications can arise immediately upon delivery.
Use in Lactation: Desvenlafaxine (O-desmethylvenlafaxine) is excreted in human milk. Because of the potential for serious adverse reactions in nursing infants from desvenlafaxine, a decision should be made whether or not to discontinue the drug, taking into account the importance of the drug to the mother. Administer desvenlafaxine to lactating women only if the expected benefits outweigh the possible risks.
Sign Out